Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 6/20 | 0.50 |
| ▸ | HTR2A | P28223 | 4/20 | 0.50 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.38 |
| ▸ | ACP3 | P15309 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.35 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8649226 | 0.83 | ESR1 (0.50) | SLC6A4HTR2AESR1ADRB2TSHR | |
| SCHEMBL8286108 | 0.82 | HTR2A (0.43) | SLC6A4HTR2AESR1CYP2D6KCNH2 | |
| SCHEMBL15247632 | 0.81 | ESR1 (0.48) | SLC6A4HTR2AESR1ADRB2TSHR | |
| SCHEMBL6114378 | 0.79 | ESR1 (0.46) | SLC6A4ESR1ADRB2TSHRACHE | |
| SCHEMBL28879943 | 0.79 | ESR1 (0.46) | SLC6A4ESR1ADRB2TSHRACHE | |
| SCHEMBL22025567 | 0.79 | CYP1A2 (0.52) | SLC6A4HTR2ACYP2D6KCNH2ALDH1A1 | |
| SCHEMBL24017153 | 0.78 | ESR1 (0.50) | SLC6A4HTR2AESR1CYP2D6KCNH2 | |
| SCHEMBL24016994 | 0.78 | ESR1 (0.50) | SLC6A4HTR2AESR1CYP2D6KCNH2 | |
| SCHEMBL25509348 | 0.77 | ESR1 (0.45) | SLC6A4HTR2AESR1ADRB2CYP2D6 | |
| SCHEMBL19820327 | 0.77 | SLC6A4 (0.40) | SLC6A4HTR2AESR1CYP2D6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12441704-B2 | Compounds active towards nuclear receptors | NUEVOLUTION A/S (DK) | 2025-10-14 | — | — | US | disclosed |
| US-20230271937-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | NUEVOLUTION A/S (DK) | 2023-08-31 | — | — | US | disclosed |
| US-20230271937-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | NUEVOLUTION A/S (DK) | 2023-08-31 | — | — | US | disclosed |
| US-20230271937-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | NUEVOLUTION A/S (DK) | 2023-08-31 | — | — | US | disclosed |
| US-11685727-B2 | Compounds active towards nuclear receptors | NUEVOLUTION A/S (DK) | 2023-06-27 | — | — | US | disclosed |
| US-11685727-B2 | Compounds active towards nuclear receptors | NUEVOLUTION A/S (DK) | 2023-06-27 | — | — | US | disclosed |
| US-11685727-B2 | Compounds active towards nuclear receptors | NUEVOLUTION A/S (DK) | 2023-06-27 | — | — | US | disclosed |
| US-20210188807-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | ALMIRALL, S.A. (ES) | 2021-06-24 | — | — | US | disclosed |
| CN-110831919-A | Epoxy methacrylate compound and use thereof | 喜利得股份公司 | 2020-02-21 | — | — | CN | disclosed |
| US-8835427-B2 | Fungicidal heterocyclic compounds | E I DU PONT DE NEMOURS AND COMPANY (US) | 2014-09-16 | — | — | US | disclosed |
| EP-2358709-B1 | FUNGICIDAL HETEROCYCLIC COMPOUNDS | DU PONT (US) | 2014-01-22 | — | — | EP | disclosed |
| US-8618137-B2 | Fungicidal heterocyclic compounds | E I DU PONT DE NEMOURS AND COMPANY (US) | 2013-12-31 | — | — | US | disclosed |
| US-20120309752-A1 | FUNGICIDAL HETEROCYCLIC COMPOUNDS | E I DU PONT DE NEMOURS AND COMPANY (US) | 2012-12-06 | — | — | US | disclosed |
| US-20110224258-A1 | FUNGICIDAL HETEROCYCLIC COMPOUNDS | E.I. DU PONT DE NEMOURS AND COMPANY (DE) | 2011-09-15 | — | — | US | disclosed |
| WO-2005058892-A1 | PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-06-30 | — | — | WO | disclosed |
| EP-1339670-A1 | SUBSTITUTED CYCLOHEXANE DERIVATES AND THE USE THEREOF IN MEDICAMENTS FOR TREATING CARDIOVASCULAR DISEASES | Bayer Aktiengesellschaft (DE) | 2003-09-03 | — | — | EP | disclosed |
| WO-2002042257-A1 | SUBSTITUTED CYCLOHEXANE DERIVATES AND THE USE THEREOF IN MEDICAMENTS FOR TREATING CARDIOVASCULAR DISEASES | BAYER AKTIENGESELLSCHAFT (DE) | 2002-05-30 | — | — | WO | disclosed |
| US-4465509-A | Urea compounds and herbicidal compositions containing them | THE JAPAN CARLIT CO., LTD. (JP) | 1984-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11685727-B2 | Compounds active towards nuclear receptors | NCOA1, NR1H2, NCOA3 | SLC6A4 4193/4885HTR2A 1544/4885ESR1 46/4885 |
| US-20110224258-A1 | FUNGICIDAL HETEROCYCLIC COMPOUNDS | NOX1, XDH, CBR1 | SLC6A4 3721/4885HTR2A 3556/4885ESR1 3154/4885 |
| US-20230271937-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | NCOA1, NR1H2, NCOA3 | SLC6A4 4193/4885HTR2A 1544/4885ESR1 46/4885 |
| US-20120309752-A1 | FUNGICIDAL HETEROCYCLIC COMPOUNDS | CYP1B1, NOX3, CYP1A1 | SLC6A4 3548/4885HTR2A 3531/4885ESR1 1934/4885 |
| US-12441704-B2 | Compounds active towards nuclear receptors | NCOA1, NR1H2, NCOA3 | SLC6A4 4193/4885HTR2A 1544/4885ESR1 46/4885 |
| US-20210188807-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | NCOA1, NR1H2, NCOA3 | SLC6A4 4193/4885HTR2A 1544/4885ESR1 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.